FI971510A - Atsolijohdannainen - Google Patents
Atsolijohdannainen Download PDFInfo
- Publication number
- FI971510A FI971510A FI971510A FI971510A FI971510A FI 971510 A FI971510 A FI 971510A FI 971510 A FI971510 A FI 971510A FI 971510 A FI971510 A FI 971510A FI 971510 A FI971510 A FI 971510A
- Authority
- FI
- Finland
- Prior art keywords
- same
- represent
- hydrogen
- different
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24948894 | 1994-10-14 | ||
JP25112194 | 1994-10-18 | ||
PCT/JP1995/002085 WO1996011916A1 (fr) | 1994-10-14 | 1995-10-12 | Derive d'azole |
Publications (2)
Publication Number | Publication Date |
---|---|
FI971510A true FI971510A (fi) | 1997-04-11 |
FI971510A0 FI971510A0 (fi) | 1997-04-11 |
Family
ID=26539322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI971510A FI971510A0 (fi) | 1994-10-14 | 1997-04-11 | Atsolijohdannainen |
Country Status (16)
Country | Link |
---|---|
US (1) | US5981559A (zh) |
EP (1) | EP0786457B1 (zh) |
JP (1) | JP3061862B2 (zh) |
KR (1) | KR100386392B1 (zh) |
CN (1) | CN1107059C (zh) |
AT (1) | ATE218132T1 (zh) |
AU (1) | AU699476B2 (zh) |
CA (1) | CA2202623A1 (zh) |
DE (1) | DE69526862T2 (zh) |
FI (1) | FI971510A0 (zh) |
HU (1) | HUT77609A (zh) |
MX (1) | MX9702670A (zh) |
NO (1) | NO309268B1 (zh) |
RU (1) | RU2161612C2 (zh) |
TW (1) | TW381088B (zh) |
WO (1) | WO1996011916A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004137284A (ja) * | 1997-06-17 | 2004-05-13 | Kaken Pharmaceut Co Ltd | 2−スルファモイル安息香酸誘導体 |
JP3527514B2 (ja) * | 1997-06-17 | 2004-05-17 | 科研製薬株式会社 | 2−スルファモイル安息香酸誘導体 |
US6376671B1 (en) | 1997-06-17 | 2002-04-23 | Kaken Pharmaceutical Co., Ltd. | 2-sulfamoylbenzoic acid derivatives |
WO2001030757A1 (fr) * | 1999-10-28 | 2001-05-03 | Microcide Pharmaceuticals, Inc. | Inhibiteurs de la pompe par liberation de medicaments |
US7176243B2 (en) * | 2000-06-02 | 2007-02-13 | The General Hospital Corporation | CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis |
US20050009843A1 (en) * | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
US7056917B2 (en) | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
WO2005027886A2 (en) * | 2003-09-17 | 2005-03-31 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
US7507531B2 (en) * | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
US7851486B2 (en) * | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
JP2006508180A (ja) * | 2002-10-17 | 2006-03-09 | デコード ジェネティクス イーエッチエフ. | 心筋梗塞に対する感受性遺伝子;治療の方法 |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
EP2308469A1 (en) * | 2005-05-18 | 2011-04-13 | Pulmatrix, Inc. | Formulations for alteration of biophysical properties of mucosal lining |
MX2009008923A (es) | 2007-02-22 | 2009-08-28 | Irm Llc | Compuestos y metodos para modular receptores acoplados por proteina g. |
US8758824B2 (en) | 2010-08-30 | 2014-06-24 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
CA2809666C (en) | 2010-08-30 | 2020-09-22 | Michael M. Lipp | Dry powder formulations and methods for treating pulmonary diseases |
PT3470057T (pt) | 2010-09-29 | 2021-12-03 | Pulmatrix Operating Co Inc | Pós secos catiónicos compreendendo sais de magnésio |
IL286573B (en) | 2010-09-29 | 2022-08-01 | Pulmatrix Operating Co Inc | Monovalent metallic cation dry powders for inhalation |
WO2013130767A1 (en) | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
EP3649142A4 (en) | 2017-07-04 | 2021-09-01 | Intocell, Inc. | JOINTS WITH SPLITABLE LINKER AND USES THEREOF |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS532613A (en) * | 1976-06-24 | 1978-01-11 | Shinkou Burain Kk | Crepe forming method for paper |
JPS63258854A (ja) * | 1987-04-16 | 1988-10-26 | Mitsubishi Kasei Corp | カルボキシスチレン誘導体およびそれを有効成分とする薬剤 |
ZA894913B (en) * | 1988-07-12 | 1990-03-28 | Ici Pharma | Heterocyclic compounds |
JPH0832688B2 (ja) * | 1990-10-16 | 1996-03-29 | テルモ株式会社 | フェノキシ酢酸誘導体及びこれを含有する医薬製剤 |
JPH0532613A (ja) * | 1991-07-29 | 1993-02-09 | Terumo Corp | フエノキシ酢酸誘導体およびこれを含有する医薬製剤 |
US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
-
1995
- 1995-10-12 AU AU36730/95A patent/AU699476B2/en not_active Ceased
- 1995-10-12 EP EP95934280A patent/EP0786457B1/en not_active Expired - Lifetime
- 1995-10-12 CN CN95195649A patent/CN1107059C/zh not_active Expired - Fee Related
- 1995-10-12 AT AT95934280T patent/ATE218132T1/de not_active IP Right Cessation
- 1995-10-12 WO PCT/JP1995/002085 patent/WO1996011916A1/ja active IP Right Grant
- 1995-10-12 CA CA002202623A patent/CA2202623A1/en not_active Abandoned
- 1995-10-12 MX MX9702670A patent/MX9702670A/es not_active IP Right Cessation
- 1995-10-12 TW TW084110701A patent/TW381088B/zh not_active IP Right Cessation
- 1995-10-12 JP JP8513092A patent/JP3061862B2/ja not_active Expired - Lifetime
- 1995-10-12 DE DE69526862T patent/DE69526862T2/de not_active Expired - Fee Related
- 1995-10-12 RU RU97107457/04A patent/RU2161612C2/ru active
- 1995-10-12 US US08/809,466 patent/US5981559A/en not_active Expired - Fee Related
- 1995-10-12 KR KR1019970701880A patent/KR100386392B1/ko not_active IP Right Cessation
- 1995-10-12 HU HU9702271A patent/HUT77609A/hu unknown
-
1997
- 1997-04-11 FI FI971510A patent/FI971510A0/fi unknown
- 1997-04-11 NO NO971685A patent/NO309268B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2202623A1 (en) | 1996-04-25 |
NO971685L (no) | 1997-06-13 |
DE69526862D1 (de) | 2002-07-04 |
FI971510A0 (fi) | 1997-04-11 |
EP0786457A4 (en) | 1997-12-29 |
CN1160397A (zh) | 1997-09-24 |
NO309268B1 (no) | 2001-01-08 |
WO1996011916A1 (fr) | 1996-04-25 |
ATE218132T1 (de) | 2002-06-15 |
US5981559A (en) | 1999-11-09 |
HUT77609A (hu) | 1998-06-29 |
MX9702670A (es) | 1997-07-31 |
AU3673095A (en) | 1996-05-06 |
JP3061862B2 (ja) | 2000-07-10 |
EP0786457A1 (en) | 1997-07-30 |
EP0786457B1 (en) | 2002-05-29 |
CN1107059C (zh) | 2003-04-30 |
AU699476B2 (en) | 1998-12-03 |
RU2161612C2 (ru) | 2001-01-10 |
KR100386392B1 (ko) | 2003-10-11 |
TW381088B (en) | 2000-02-01 |
DE69526862T2 (de) | 2003-01-02 |
NO971685D0 (no) | 1997-04-11 |
KR970706265A (ko) | 1997-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO971685D0 (no) | Azolderivat | |
NO940737D0 (no) | Antidepressive midler | |
WO2002023986A1 (fr) | Derives de 4-acylaminopyrazole | |
DE69331414D1 (de) | Depsipeptide, herstellung und anwendung | |
CA2311742A1 (en) | 6-amino-9-benzyl-8-hydroxypurine derivatives | |
ES2156155T3 (es) | Derivado de pirazol. | |
AR002761A1 (es) | Un compuesto derivado del triazol, su uso, una composicion farmaceutica que lo contiene, un metodo de tratamiento o prevencion de una infeccion fungica enun paciente humano mediante dicho compuesto o composicion, y procedimiento y compuestos intermedios para prepararlo. | |
NO304486B1 (no) | Oksazolidonderivater og anvendelser derav, og midler og medisinske preparater omfattende slike oksazolidonderivater | |
ATE169623T1 (de) | Dihydrobenzofuranderivate, ihre herstellung und verwendung | |
ATE194912T1 (de) | Mittel zur vorsorge und heilung von typ i allergischen krankheiten | |
DK0554794T3 (da) | Aminobenzoesyrederivater | |
ATE86117T1 (de) | Zusammensetzung gegen leberkrankheiten. | |
HUT46511A (en) | Fungicides comprising pyridyl-cyclopropane-carboxamide derivatives as active ingredient | |
DE69327077D1 (de) | Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen | |
DE69325083D1 (de) | Imidazol-Derivate und ihre Verwendung als agrochemische Mittel | |
ATE241985T1 (de) | Therapeutisches mittel zur behandlung von nierenerkrankungen | |
DE60026559D1 (de) | Arzneimittel gegen essstörungen | |
ATE177106T1 (de) | Ymidothiophosphat-derivat und insektizid, nematozid und akarizid enthalted dasselbe als aktiven bestandteil. |